Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A B Rossi

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
FEBS Letters|March 21, 2000
Rab37 is a novel mast cell specific GTPase localized to secretory granulesE S Masuda, Y Luo, C Young, et al.
Genetics and Molecular Research : GMR|May 27, 2017
Morphological descriptors and ISSR molecular markers in the evaluation of genetic variability of Tectona grandis genotypesA M Chimello, J G Jesus, P E Teodoro, et al.
The Journal of Dermatological Treatment|April 30, 2020
Dupilumab provides rapid and sustained improvement in SCORAD outcomes in adults with moderate-to-severe atopic dermatitis: combined results of four randomized phase 3 trialsS Barbarot, A Wollenberg, J I Silverberg, et al.
The British Journal of Dermatology|February 6, 2019
Improvement of atopic dermatitis with dupilumab occurs equally well across different anatomical regions: data from phase III clinical trialsA Blauvelt, D Rosmarin, T Bieber, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 24, 2008
Control of atopic eczema with pimecrolimus cream 1% under daily practice conditions: results of a > 2000 patient studyJ Ring, A Abraham, C de Cuyper, et al.
Cytometry|July 15, 1999
Quantitative measurement of mast cell degranulation using a novel flow cytometric annexin-V binding assayS D Demo, E Masuda, A B Rossi, et al.
European Journal of Cancer Care|August 24, 2017
Efficacy of a global supportive skin care programme with hydrotherapy after non-metastatic breast cancer treatment: A randomised, controlled studyF Dalenc, V Ribet, A B Rossi, et al.
The British Journal of Dermatology|August 14, 2019
Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS)A Wollenberg, L A Beck, A Blauvelt, et al.
The British Journal of Dermatology|June 2, 2020
Assessing the need for routine safety testing for patients being treated with dupilumab for moderate-to-severe atopic dermatitisA Wollenberg, L A Beck, A Blauvelt, et al.
The British Journal of Dermatology|February 22, 2019
Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trialsJ I Silverberg, E L Simpson, M Ardeleanu, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
FEBS Letters|March 21, 2000
Rab37 is a novel mast cell specific GTPase localized to secretory granulesE S Masuda, Y Luo, C Young, et al.
Genetics and Molecular Research : GMR|May 27, 2017
Morphological descriptors and ISSR molecular markers in the evaluation of genetic variability of Tectona grandis genotypesA M Chimello, J G Jesus, P E Teodoro, et al.
The Journal of Dermatological Treatment|April 30, 2020
Dupilumab provides rapid and sustained improvement in SCORAD outcomes in adults with moderate-to-severe atopic dermatitis: combined results of four randomized phase 3 trialsS Barbarot, A Wollenberg, J I Silverberg, et al.
The British Journal of Dermatology|February 6, 2019
Improvement of atopic dermatitis with dupilumab occurs equally well across different anatomical regions: data from phase III clinical trialsA Blauvelt, D Rosmarin, T Bieber, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 24, 2008
Control of atopic eczema with pimecrolimus cream 1% under daily practice conditions: results of a > 2000 patient studyJ Ring, A Abraham, C de Cuyper, et al.
Cytometry|July 15, 1999
Quantitative measurement of mast cell degranulation using a novel flow cytometric annexin-V binding assayS D Demo, E Masuda, A B Rossi, et al.
European Journal of Cancer Care|August 24, 2017
Efficacy of a global supportive skin care programme with hydrotherapy after non-metastatic breast cancer treatment: A randomised, controlled studyF Dalenc, V Ribet, A B Rossi, et al.
The British Journal of Dermatology|August 14, 2019
Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS)A Wollenberg, L A Beck, A Blauvelt, et al.
The British Journal of Dermatology|June 2, 2020
Assessing the need for routine safety testing for patients being treated with dupilumab for moderate-to-severe atopic dermatitisA Wollenberg, L A Beck, A Blauvelt, et al.
The British Journal of Dermatology|February 22, 2019
Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trialsJ I Silverberg, E L Simpson, M Ardeleanu, et al.
Pageof 4